New bicyclam-AZT conjugates: Design, synthesis, anti-HIV evaluation, and their interaction with CXCR-4 coreceptor

Journal of Medicinal Chemistry

Volumn 42, Issue 2, 1999, Pages 229-241

  Dessolin, Jean ^a,b   Galea, Pascale ^b   Vlieghe, Patrick ^a,b   Chermann, Jean Claude ^b   Kraus, Jean Louis ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3' AZIDO 3' DEOXY 5' O [5 [1,4,8,11 TETRAHYDROCHLORIDE 11 [4 [(1,4,8,11 TETRAHYDROCHLORIDE 1,4,8,11 TETRAAZACYCLOTETRADECANYL)METHYL]BENZYL] 1,4,8,11 TETRAAZACYCLOTETRADECANYL]PENTANOYL]THYMIDINE; ANTIVIRUS AGENT; UNCLASSIFIED DRUG; ZIDOVUDINE; ZIDOVUDINE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG STABILITY; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; VIRUS INHIBITION; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELL LINE; DRUG DESIGN; HETEROCYCLIC COMPOUNDS; HIV-1; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; RECEPTORS, CXCR4; SPECTROMETRY, MASS, FAST ATOM BOMBARDMENT; VIRUS REPLICATION; ZIDOVUDINE;

EID: 0032959833     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980358u     Document Type: Article

References (28)

1. De Clercq, E. In search of a selective antiviral chemotherapy. Clin. Microbiol. Rev. 1997, 10, 674-693.
2. Srinivas, R. V.; Bernstein, H.; Oliver, C.; Compans, R. Calmodulin antagonists inhibit human immunodeficiency virus-induced cell fusion but not virus replication. AIDS Res. Hum. Retroviruses 1994, 10, 1489-1496.
3. De Clercq, E.; Yamamoto, N.; Pauwels, R.; Baba, M.; Schols, D.; Nakashima, H.; Balzarini, J.; Debyser, Z.; Murrer, B. A.; Schwartz, D.; Thornton, D.; Bridger, G.; Fricker, S.; Henson, G.; Abrams, M.; Picker, D. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 5286-5290.
4. De Clercq, E.; Yamamoto, N.; Pauwels, R.; Balzarini, J.; Witvrouw, M.; De Vreese, K.; Debyser, Z.; Rosenwirth, B.; Peichl, P.; Datema, R.; Thornton, D.; Skerlj, R.; Gaul, F.; Padmanabhan, S.; Bridger, G.; Henson, G.; Abrams, M. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM 3100. Antimicrob. Agents Chemother. 1994, 38, 668-674.
5. De Clercq, E. Human immunodeficiency virus inhibitors targeted at a virus-cell fusion and/or viral uncoating. Int. J. Immunother. 1992, VIII, 115-123.
6. De Vreese, K.; Kofler-Mongold, V.; Leutgeb, C.; Weber, C.; Vermeire, K.; Schacht, S., Anné, J.; De Clercq, E.; Datema, R.; Werner, G. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J. Virol. 1996, 70, 689-696.
7. De Vreese, K.; Reymen, D.; Griffin, P.; Steinkasserer, A.; Werner, G.; Bridger, G. J.; Esté, J.; James, W.; Henson, G. W.; Desmyter, J.; Anné, J.; De Clercq, E. The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding. Antiviral. Res. 1996, 29, 209-219.
8. Esté, J.; De Vreese, K.; Witvrouw, M.; Schmit, J.-C.; Vandamme, A.-M.; Anné, J.; Desmyter, J.; Henson, G. W.; Bridger, G. J.; De Clercq, E. Antiviral activity of the bicyclam derivative JM 3100 against drug-resistant strains of human immunodeficiency virus type 1. Antiviral. Res. 1996, 29, 297-307.
9. Trabaud, C.; Dessolin, J.; Camplo, M.; Hantz, O.; Zoulim, F.; Borel, C.; Meyer, M.; Pepe, G.; Chermann, J.-C.; Kraus, J.-L. Design, synthesis and structure relationships of new N,N′,N″,N‴-tetrakis(ω-aminoalkyl)tetraazamacrocycles. Antiviral Chem., Chemother. 1997, 9, 73-84.
10. De Clercq, E. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J. Med. Chem. 1995, 38, 2491-2517.
11. Schols, D.; Esté, J.; Henson, G.; De Clercq, E. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor Fusin/CXCR-4. Antiviral Res. 1997, 35, 147-156.
12. Schols, D.; Struyf, S.; Van Damme, J.; Esté, J. A.; Henson, G.; De Clercq, E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR-4. J. Exp. Med. 1997, 186, 1383-1388.
13. De Vreese, K.; Van Nerum, I.; Vermeire, K.; Anné, J.; De Clercq, E. Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120. Antimicrob. Agents Chemother. 1997, 41, 2616-2620.
14. Derivati 1,3-ossatiolanici ad attività antivirale. Italian Patent No. MI0075137, 1997.
15. Harada, S.; Yamamoto, N.; Koyanagi, Y. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque-assay. Science 1985, 229, 565-566.
16. Zimmerman, T. P.; Mahony, W. B.; Prus, K. L. 3′-azido-3′-deoxythymidine. An unusual nucleoside analogue that permeates the membrane of human-erythrocyctes and lymphocytes by nonfacilitated diffusion. J. Biol. Chem. 1987, 262, 5748-5754.
17. Feng, Y.; Broder, C. C.; Kennedy, P. E.; Berger, E. A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane G protein-coupled receptor. Science 1996, 272, 872-877.
18. Dessolin, J.; Quelever, G.; Camplo, M.; Kraus, J.-L. Syntheses of new unsymmetrical bispolyazamacrocycles. Tetrahedron Lett. 1998, 39, 853-856.
19. Boitrel, B.; Andrioletti, B.; Lachkar, M.; Guilard, R. Characterization and application of a new diprotected cyclam: a novel two-step synthesis of linked tetraazamacrocycles. Tetrahedron Lett. 1995, 35, 4995-4998.
20. Bridger, G. J.; Skerlj, R. T.; Thornton, D.; Padmanabhan, S.; Martellucci, S. A.; Henson, G. W.; Abrams, M. J.; Yamamoto, N.; De Vreese, K.; Pauwels, R.; De Clercq, E. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker. J. Med. Chem. 1995, 38, 366-378.
21. Aggarwal, S.; Gogu, S.; Rangan, S.; Agrawal, K. Synthesis and biological evaluation of prodrugs of zidovudine. J. Med. Chem. 1990, 33, 1505-1510.
22. Dessolin, J.; Vlieghe, P.; Bouygues, M.; Medou, M.; Quéléver, G.; Camplo, M.; Chermann, J. C.; Kraus J. L. Tri-N-Boctetraazamcrocycle-nucleoside conjugates: synthesis and anti-HIV activities. Nucleosides Nucleotides 1998, 17, 957-968.
23. Moore, J. P.; Trkola, A.; Dragic, T. Co-receptors for HIV-1 entry. Curr. Opin. Immunol. 1997, 9, 551-562.
24. Vandamme, J.; Proost, P.; Lenaerts, J. P.; Opdenakker, G. Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemotactic family. J. Exp. Med. 1992, 176, 59-65.
25. Barré-Sinoussi, F.; Chermann, J.-C.; Rey, F.; Nugeyre, M. T.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler-Blin, C.; Brun-Vezinet, F.; Rouzioux, C.; Rosenbaum, W.; Montagnier, L. Isolation of a T-lymphotropic retrovirus from a patient at risk of acquired immunodefficiency syndrome. Science 1983, 220, 868-871.
26. 4 cells. J. Virol. Methods 1987, 16, 239-249.
27. + cells by selected HIV strains is not inhibited by anti-CD4 monoclonal antibodies. Virology 1991, 181, 165-171.
28. Seki, J.-I.; Ikeda, R.; Hoshino, H. Dimethyl sulfoxyde and related polar compounds enhance infection of human T cells with HIV-1 in vitro. Biochem. Biophys. Res. Commun. 1996, 227, 724-729.